Relief therapeutics « Terug naar discussie overzicht

Relief therapeutics Holding

7.692 Posts, Pagina: « 1 2 3 4 5 6 7 ... 381 382 383 384 385 » | Laatste
Kabbas
0

BRIEF-Relief Therapeutics Filing Of IND For Phase 2/3 Clinical Trial Of Inhaled RLF-100

07:13 (11/05) - Bron: Reuters



May 11 (Reuters) - RELIEF THERAPEUTICS Holding SA RLFB.S :
* ANNOUNCES FILING OF IND FOR PHASE 2/3 CLINICAL TRIAL OF
INHALED
RLF-100 TARGETING EARLY COVID-19 LUNG INJURY

Source text - bit.ly/2AhHPBP
Further company coverage:

(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;;))

N13k
0
www.businesswire.com/news/home/202006...


Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF- 100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress
MisterBlues
0
Goed teken dat ze de eerste site zo voortvarend hebben kunnen opstarten:

University of Miami Miller School of Medicine

Als ze de andere ziekenhuizen / universitaire medische centra nu ook snel in beweging krijgen is dat een sterke indicatie dat er geloof is in dit middel. Nog te gaan:

  • University of California;
  • Irvine and Thomas Jefferson University Hospital, Philadelphia.
Kabbas
0
Klopt goed nieuws vandaag.
Ben benieuwd, aangezien Gilead hun medicijn niet goed werkte zijn de verwachtingen hoog gespannen
MisterBlues
0
@Kabbas, heb jij onderzoek gedaan naar dit aandeel?

Waarom zijn ze zo afgegleden naar een pennystock?

Is hun kandidaat-medicijn tegen de gevolgen van de cytokinestorm als gevolg van Covid-19 eerder een wanhoopspoging of een kansrijke oprechte actie?

Voor mij is dit voorlopig gewoon een gok-aandeel.
MisterBlues
0

Relief Therapeutics and NeuroRx Expand Clinical Trial Evaluating RLF-100 in Critically Ill COVID-19 Patients with Respiratory Failure to Houston Methodist Hospital...............

relieftherapeutics.com/relief-therape...

by Relief Therapeutics | Jun 11, 2020

Clinical trial to enroll 144 patients total with expansion to additional sites
Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in Critical COVID-19.
RLF-100 is a patented formulation of Aviptadil (synthetic human Vasoactive Intestinal Polypeptide VIP), which inhibits pro-inflammatory cytokines and protects alveolar type-2 cells in the lungs inhibiting pro-inflammatory cytokines. Type 2 cells are essential to oxygen exchange and are preferentially targeted by the SARS-CoV-2 virus



HOUSTON, June 11, 2020 – RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” and its U.S. partner, NeuroRx, Inc. today announced that Houston Methodist Hospital is participating in their Phase 2 clinical trial evaluating RLF-100 as a research intervention for critically ill patients with COVID-19 and respiratory failure. RLF-100 is a patented formulation of Aviptadil, (synthetic human vasoactive intestinal polypeptide or VIP), which targets alveolar type 2 cells in the lungs that are a major target of the SARS-CoV-2 virus. VIP is known from numerous animal models of lung injury and lung disease to inhibit inflammatory cytokines and to protect pulmonary epithelial cells that line the air sacs (alveolae) of the lungs.

The multicenter clinical trial will enroll patients with COVID-19 and respiratory failure in the hopes that RLF-100 can decrease mortality in this condition and help to improve the ability of the patient’s lungs to transfer oxygen to the body. Based on recent FDA guidance, the trial has been expanded to include patients treated with high flow nasal oxygen and noninvasive forms of ventilation, instead of only enrolling patients on mechanical ventilators.

The Principal Investigator at Houston Methodist Hospital is J. George Youssef, M.D., assistant professor of Critical Care Medicine & Pulmonology. Dr. Youssef was a co-investigator in the earlier study evaluating RLF-100 as a treatment for Acute Respiratory Distress (ARDS), a primary cause of COVID-19 related deaths, under the late Professor Sami Said, who discovered VIP in 1970 and treated the first patients.

“ We are encouraged by findings from the previous clinical trial of RLF-100 as a treatment for ARDS in patients with sepsis which showed seven out of eight patients on mechanical ventilation experienced substantial improvement and six ultimately left the hospital alive,” Dr. Youssef said. “If the early ARDS results can be replicated in critically ill COVID-19 patients with respiratory failure, this approach could present a significant advancement in the treatment of these patients.”

Jonathan Javitt, M.D., MPH, CEO of NeuroRx, added, “We at NeuroRx are enormously excited to have Dr. Youssef join our study, in light of his long involvement in the VIP story. While we can read about Dr. Said’s breakthrough, Dr. Youssef witnessed it firsthand and participated in the early clinical care of patients. It’s rare to have science come full circle in service of patients.”

The trial is being led by NeuroRx, Inc., the US development partner of Relief Therapeutics, whose clinical operations are based in Radnor, PA. Patients are being treated under an FDA Investigational New Drug clearance, as part of the FDA’s Corona Treatment Acceleration Program (CTAP). Details of the study are posted on clinicaltrials.gov NCT04311697.
MisterBlues
0
quote:

Kabbas schreef op 25 juni 2020 15:20:


+23%


Aandeel heeft de koerstoename weten vast te houden richting einde van de dag:
47,69 %
Reader
0
Goede avond, dit was leuk dankzij het nieuws van gister.
Ik had nog een order staan voor een pluk erbij maar om exact half zes was ie weg terwijl er volgens mij nog een kwartier te gaan was. Hoe kan dat?
MisterBlues
0
Veel voorkomende redenen hiervoor kunnen zijn:

- De opgegeven limiet wijkt te veel af van de huidige koers
- De ticksize is onjuist
- De order is ingelegd tijdens de Trading-At-Last (TAL) fase

Dan zou - theoretisch - een bedrijf nog ex-dividend kunnen zijn gegaan maar daar is hier natuurlijk geen sprake van. :)
Reader
0
@MisterBlues,

Dank voor je reactie,

Vertraagde koersinfo, dus lastig een relevante limiet op te geven maar lag in de buurt van de biedkoers. Maar die is dus ook vertraagd. Tickersize was goed, en de order was opgegeven ca 17:16.

Dan loopt alles nog door tot 17:45 Nederlandse tijd en om exact 17:30 was mijn order foetsie.

Heel raar maar het zal best kloppen. In elk geval bedankt voor de genomen moeite!

Mvg,

Reader
7.692 Posts, Pagina: « 1 2 3 4 5 6 7 ... 381 382 383 384 385 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 16 apr 2021 17:31
Koers 0,248
Verschil -0,001 (-0,40%)
Hoog 0,250
Laag 0,240
Volume 11.111.166
Volume gemiddeld 26.082.332
Volume gisteren 8.438.886

Brussel real time stocks quotedata by Euronext. Other real time EU stocks, by Cboe Europe Ltd.; US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront